Research Library

Exenatide is a synthetic incretin mimetic that functions as a potent agonist of the GLP-1 receptor to modulate glucose metabolism.

Liraglutide is a long-acting GLP-1 receptor agonist that mimics incretin hormones to regulate glucose metabolism and appetite.

Lixisenatide is a synthetic GLP-1 receptor agonist primarily utilized for glycemic control in type 2 diabetes, with emerging research into its potential neuroprotective applications.

Dulaglutide is a long-acting GLP-1 receptor agonist designed to mimic endogenous incretin hormones for the management of glycemic control.

Pramlintide is a synthetic analog of the pancreatic hormone amylin that modulates postprandial glucose metabolism.

Cagrilintide is an investigational long-acting amylin analogue designed to modulate satiety and body weight through central receptor pathways.

DHT-derived AAS with high anabolic ratio; non-aromatizable

Potent 19-nor AAS; non-aromatizable with high AR affinity

DHT-derived AAS with low androgenic profile; non-aromatizable

Testosterone analog with enhanced erythropoiesis; moderate aromatization

DHT-derived AAS with anti-estrogenic properties; non-aromatizable

Benzothiophene SERM; no endometrial agonist activity

Triphenylethylene SERM; tamoxifen analog with reduced endometrial risk

Early aryl propionamide SARM; anabolic with ocular side effects

Steroidal SARM inducing follistatin; myostatin pathway modulator

PPARδ agonist; metabolic and endurance research (non-SARM)

Nonsteroidal aromatase inhibitor; blocks estrogen biosynthesis

Type II 5-alpha reductase inhibitor; reduces DHT conversion

Dual 5-alpha reductase inhibitor (types I and II)

Biguanide AMPK activator; insulin sensitizer and metabolic regulator

Vitamin K antagonist; oral anticoagulant with narrow therapeutic window

Aldosterone receptor antagonist with antiandrogenic properties

HMG-CoA reductase inhibitor; lipid-lowering statin

Synthetic thyroxine (T4); thyroid hormone replacement

Primary endogenous androgen esterified for sustained depot release

19-nortestosterone with reduced androgenic and enhanced anabolic profile

Oral 17-alpha alkylated DHT derivative with high anabolic ratio

Triphenylethylene SERM; tissue-selective estrogen antagonist/agonist

Mixed SERM used to stimulate endogenous gonadotropin release

Non-steroidal SARM with tissue-selective anabolic activity

Potent non-steroidal SARM with neuroprotective properties

Potent oral SARM with significant lean mass effects in Phase I trials

Neuropeptide modulating social bonding, trust, and sexual arousal via oxytocin receptors.

Melanocortin receptor agonist acting on CNS pathways to influence sexual arousal.

Upstream regulator of GnRH neurons and the hypothalamic-pituitary-gonadal axis.

PDE5 inhibitor enhancing nitric oxide-mediated vasodilation in erectile tissue.

Non-selective melanocortin receptor agonist studied for tanning and libido effects.

Pineal-derived tripeptide targeting CNS neuroprotection, cognition, and circadian regulation

Adamantane-modified anxiolytic peptide with enhanced membrane permeability and prolonged half-life

GHK-Cu focused blend for collagen synthesis and tissue remodeling research.

Comprehensive recovery blend targeting tissue repair and anti-inflammatory signaling.

Nootropic peptide blend combining BDNF-upregulating and neuroprotective compounds.

Aggressive recovery and regeneration blend for rapid tissue repair research.

Multi-peptide recovery blend combining BPC-157 and TB-500 class compounds.

Synergistic GHRH + GHRP combination for optimized pituitary GH pulse stimulation.

Curated blend of complementary immune-modulating peptides for comprehensive research protocols.

The BPC compound class studied for gastrointestinal cytoprotection and systemic healing.

Spadin-derived peptide blocking TREK-1 channels. Studied for neuroplasticity and mood research.

Triple monoamine reuptake inhibitor examined for CNS approach to appetite signaling.

Modified C-terminal GH fragment studied for selective fat metabolism activity.

A thymic polypeptide complex studied for immune restoration in aging research.

A naturally occurring antimicrobial cathelicidin peptide with dual antimicrobial and immune signaling activity.

Cagrilintide + semaglutide combination. REDEFINE 1: 22.7% mean body weight loss at 68 weeks.

Dual GLP-1/glucagon receptor agonist. Phase 3 SYNCHRONIZE-1: 16.6% weight loss.

Second-generation hexapeptide GHRP with superior potency. Approved in Japan as Pralmorelin.

The pioneer hexapeptide that launched the GHRP class and indirectly led to the discovery of ghrelin.

A cyclic α-MSH analog activating MC1R, MC3R, MC4R. Key research tool in melanocortin pharmacology.

FDA-approved Bremelanotide (Vyleesi 2019) — acts via central nervous system melanocortin pathways.

An angiotensin IV analog studied for synaptogenesis via the HGF/MET signaling pathway.

The only orally active GH secretagogue. Studied in multiple Merck clinical trials.

FDA-approved GHRH analog (Egrifta) for visceral fat reduction with Phase III clinical trial data.

A copper-binding tripeptide studied for collagen synthesis, gene expression modulation, and tissue remodeling.

A tripeptide derived from alpha-MSH, studied for anti-inflammatory signaling via NF-κB inhibition.

N-Acetyl Semax Amidate — enhanced Semax derivative studied for cognitive enhancement and neuroplasticity.

A synthetic heptapeptide derived from tuftsin, studied for GABAergic system influence and BDNF expression.

Approved as Zadaxin in over 35 countries. One of the most extensive clinical research bodies in immune support.

The first peptide discovered to be encoded within mitochondrial DNA. Studied for neuroprotection and insulin sensitivity.

Concentrates ~1,000-fold in the inner mitochondrial membrane. One of the most clinically advanced mitochondria-targeted peptides.

A mitochondrial-derived peptide linked to cellular energy regulation. Encoded in mitochondrial DNA.

A coenzyme essential to cellular energy production, DNA repair, and sirtuin activation.

A synthetic GHRH analog with Drug Affinity Complex technology for extended half-life.

A long-acting GLP-1 receptor agonist with one of the most extensive research bodies of any modern peptide.

A triple-receptor agonist (GLP-1, GIP, glucagon) — one of the most potent metabolic peptides in current research.

A dual GLP-1/GIP receptor agonist at the forefront of metabolic research.

The original synthetic GHRH analog with FDA approval history as Geref.

Synthetic fragment studied for actin regulation, cell migration, and tissue repair signaling.

A synthetic ACTH fragment studied for neuroprotection and BDNF upregulation. Pharmaceutical approval in Russia for stroke recovery.

The most selective GHRP in widespread research use — stimulates natural-pattern GH pulses without cortisol or prolactin side effects.

FDA Cat. 1 Restored April 2026. A 15-amino-acid pentadecapeptide with 300+ preclinical papers.

A four-amino-acid peptide derived from pineal gland research in Russia, now studied globally for telomerase activation and telomere biology.